Michael Byrne
A5040815890- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- RNA regulation and disease
- interferon and immune responses
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- RNA Interference and Gene Delivery
- Cancer Genomics and Diagnostics
- Corneal Surgery and Treatments
- Mesenchymal stem cell research
- RNA Research and Splicing
Tennessee Oncology
2024-2025
Rutgers, The State University of New Jersey
2025
Vanderbilt University Medical Center
2015-2024
Vanderbilt University
2016-2023
United States Marine Corps
2022
Partners In Care
2022
University of Newcastle Australia
2022
Vanderbilt-Ingram Cancer Center
2016-2021
Patient Advocate Foundation
2020
University of Florida
2012-2018
A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is required to select optimal patient groups in clinical trials, monitor progression and response treatment, better plan care. Blood an attractive source biomarkers due minimal discomfort the patient, encouraging greater compliance trials frequent testing. MiRNAs belong class non-coding regulatory RNA molecules ∼22 nt length are now recognized regulate ∼60% all known genes through post-transcriptional gene...
Outcomes are poor in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT). Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator.We conducted phase II, multicenter, open-label trial to assess efficacy safety of eprenetapopt combined with azacitidine as maintenance therapy HCT (ClinicalTrials.gov identifier: NCT03931291). Patients mTP53 MDS or AML received up 12 cycles 3.7 g...
Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of
Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling (MSD) is still considered the optimal donor. Using Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) first complete remission (CR1). Data from 1205 adult CR1 AML (2008-2015) were analyzed. A total...
Abstract Allogeneic hematopoietic cell transplant is a potential curative therapy for acute lymphoblastic leukemia (ALL). Delineating the graft-versus-leukemia (GVL) effect as function of graft-versus-host disease (GVHD) offers to improve survival. We examined 5215 recipients with ALL reported Center International Blood and Marrow Transplant Research registry. Overall survival (OS) was compared according presence severity GVHD evaluated in 3 cohorts: 2593 adults first or second complete...
Advanced hepatocellular cancer (HCC) is an incurable disease with limited options for systemic treatment. Sorafenib was approved advanced HCC based on trials in patients Child-Pugh class A. We reviewed our experience retrospectively who were treated sorafenib a focus B (CP-B) liver cirrhosis and effect of hypertension (HTN) survival.We medical charts documented received since 2007. Survival data plotted according to HTN.Results 41 39% had CP-B. Eighty-five percent male 67% due viral...
For patients with high risk myeloid disease, allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy. Unfortunately, many of these relapse after HCT and have a limited survival. The recent approval venetoclax, an orally bioavailable BCL-2 inhibitor, resulted in significant responses treatment naïve acute leukemia (AML), off-label use relapsed/refractory setting increasing. We report outcomes 21 who underwent for relapsed AML, were treated venetoclax....
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from Center International Blood and Marrow Transplant Research on adult patients acute myeloid leukemia, lymphoblastic myelodysplastic syndrome, or chronic leukemia who...
The purpose of this study was to determine whether laser Doppler skin perfusion pressure (LD-SPP) could accurately predict amputation wound healing.We studied a total 62 limbs in 52 patients (28 men and 24 women) with mean age 62.2 years (range 34 93 years). From this, 39 underwent major (15 above-the-knee, below-the-knee), 23 minor amputations (4 transmetatarsal 19 toes). There were five postoperative deaths, leaving 57 available for analysis.Three 13 above-knee failed heal. Twenty-one...
The application of machine learning in medicine has been productive multiple fields, but not previously applied to analyze the complexity organ involvement by chronic graft-versus-host disease. Chronic disease is classified an overall composite score as mild, moderate or severe, which may overlook clinically relevant patterns involvement. Here we a novel computational approach with goal identifying phenotypic groups based on subcomponents National Institutes Health Consensus Criteria....
Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) sensitize to subsequent chemotherapy, we hypothesized therapy before ASCT would result in acceptable outcomes among high-risk who progressed or responded insufficiently ≥1 salvage regimen, including chemorefractory are traditionally considered poor candidates. We retrospectively identified 78 HL...
Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes patients with occurring after Haplo transplantation PTCy prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor conventional (MUD/conventional). We evaluated 2 cohorts: grade 4 acute (aGvHD) including 264 1163 recipients of MUD...
Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned guadecitabine or preselected treatment choice (TC) of high-intensity chemotherapy, low-intensity HMAs low-dose cytarabine, best supportive care (BSC). The primary end point was overall survival (OS). A total 302 patients (n = 148) TC 154). Preselected TCs 233 [77%; mainly HMAs]), chemotherapy 63 [21%]), and...
The toxicity of chimeric antigen receptor-natural killer (CAR-NK) therapy has not been tested in solid tumors, compared with CAR-T side by side. To address this, we investigated the CD147-CAR-NK "on-target/off-tumor" and neurotoxicity human CD147-transgenic (hCD147TG) mice hepatocellular carcinoma (HCC). We first vitro cytotoxicity against CD147+ tumor healthy cells. Both cells CD147-IL15-CAR-NK (autocrine expressing interleukin [IL]-15) can kill specifically but lung spleen tissue from...
This Viewpoint discusses the need to bring chimeric antigen receptor T-cell (CAR-T) therapy community oncology, which will allow an uninterrupted continuum of care for patients.